NCT01204749

Who might be able to join this trial:

• You are a woman aged 18 or older at the time you sign the consent form
• You are in good enough general health to carry out light activity and care for yourself (your doctor will assess this)
• Your doctor expects you to live for at least 3 months or longer
• You have been diagnosed with invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, confirmed by a tissue or cell sample
• You have had surgery for your cancer that included removal of at least one ovary
• Your cancer can be seen and measured on a scan
• You have received one prior chemotherapy treatment containing a platinum-based drug (such as carboplatin or cisplatin) for your cancer
• Your kidneys, liver, blood, and other organs are functioning well enough to participate
• Your blood pressure is generally well controlled, with readings at or below 140/90 mmHg (blood pressure medication to help control this is allowed)
• Your scans show that your cancer has grown or spread either during or after your most recent chemotherapy treatment

Who may not be able to join:

• You have received more than 3 separate anti-cancer treatments for your ovarian, peritoneal, or fallopian tube cancer
• You have previously received paclitaxel on its own or as a maintenance or consolidation treatment
• Your cancer did not respond to platinum-based chemotherapy from the very beginning (primary platinum-refractory disease — confirm with trial site)
• It has been more than 12 months since your last platinum-based chemotherapy
• You have had radiotherapy within the last 14 days before joining the trial, or you have not fully recovered from its side effects
• You have previously had radiotherapy to your abdomen or pelvis at any time
• You have had a blood clot in an artery or vein within the past 12 months
• You have had a significant bleeding episode within the past 6 months
• Your cancer has spread to your brain or central nervous system
• You have not waited at least 21 days after finishing your last cancer treatment before joining (or 30 days if that treatment included bevacizumab)
• You are currently in another clinical trial or have not waited at least 30 days since finishing one
• You still have significant side effects (grade 2 or higher) from previous cancer treatments, apart from hair loss
• You have had an active infection (other than a simple urinary tract infection) within the last 14 days
• You have previously been treated with AMG 386 or similar drugs that target the same biological pathway (angiopoietins or Tie2 receptor — confirm with trial site)
• You have taken strong immune-suppressing medications (such as cyclosporine, methotrexate, thalidomide, or similar drugs) within the last 30 days
• You have had a significant heart or blood vessel problem within the past 12 months
• You have had major surgery within the last 28 days, or you are still recovering from surgery
• You have had a minor surgical procedure (other than insertion of a central line or a diagnostic laparoscopy) within the last 3 days
• Your cancer type is pseudomyxoma, mesothelioma, sarcoma, neuroendocrine, unknown primary, borderline (low malignant potential), clear cell, or mucinous (these specific cancer types are not eligible)

Important: Always verify eligibility with the trial site directly before applying.